Membrane Hsp70: Unique, Novel Tumor-Specific Biomarker
Our lead clinical stage natural killer (NK) cell therapy, is an autologous platform technology that activates NK cells to kill cancers expressing a unique membrane form of Heat Shock Protein 70 (mHsp70).
Heat shock protein 70 (Hsp70) is a chaperone protein produced intracellularly by cells in response to exposure to stressful physiological conditions. Hsp70 has been discovered to be highly expressed on the cell membrane (mHsp70) of a variety of different cancer types, but not on the surface of normal cells.
Metastatic cancers, which are responsible for ~90% of all cancer related deaths, and therapy-resistant disease express the highest levels of membrane Hsp70. Radiation and chemotherapy increases mHsp70 expression and renders tumors more sensitive to therapeutics targeting mHsp70.
Alphageneron has entered into an exclusive worldwide license with Multimmune GmbH of Munich, Germany for its therapeutic and diagnostic technology targeting membrane Hsp70.